A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 2 news outlets

twitter: 2 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 34 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,273 followers.

7/ One of the clinical trials I worked on was high dose IL-2 (Proleukin) in stage III and IV melanoma patients. According to the linked article, the complete response rate is around 3% for this therapy. https://t.co/PlzMNkHCAo

04 Apr 2018

Reply Repost Favourite

#JITC: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma https://t.co/o5Ry6ZbNwa

05 Oct 2016

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.